Mitochondrial transplantation as a strategy to address metabolic decline in aging
May 10, 2025 / Mitochondrial transplantation / Aging metabolism therapy / Adipose tissue dysfunction / Insulin resistance treatment / Exosome-based therapy
This review explores mitochondrial transplantation via exosome cargo as a novel strategy to counter metabolic decline, inflammation, and insulin resistance in aging, aiming to restore adipose tissue function and enhance metabolic health.
Metabolic mediators of the overweight’s effect on infertility in women with polycystic ovary syndrome
May 9, 2025 / PCOS infertility / Metabolic mediators / BMI and fertility / Triglycerides HDL FBS / Insulin resistance in PCOS
This study quantifies how triglycerides, HDL, and fasting blood sugar mediate the link between elevated BMI and infertility in women with PCOS, highlighting metabolic dysfunction as a key therapeutic target to improve fertility outcomes.
Bigger bellies in childhood linked to development of metabolic and heart health risk by 10 years old
May 12, 2025 / Childhood obesity risk / Waist-to-height ratio / Pediatric metabolic health / Central obesity children / Cardiometabolic markers kids
Elevated waist-to-height ratio in children—particularly those with gradual central fat gain—is linked to higher cardiometabolic and cardiovascular risk by age 10, highlighting central obesity as a key early marker for metabolic dysfunction.
Maternal cardiometabolic health during pregnancy associated with higher blood pressure in children, NIH study finds
May 8, 2025 / Maternal health pregnancy / Childhood blood pressure risk / Gestational diabetes effects / Cardiometabolic risk children / Prenatal hypertension impact
Maternal cardiometabolic conditions—like obesity, gestational diabetes, and hypertension—are linked to higher blood pressure in children, potentially predisposing them to long-term cardiovascular risk, according to a large NIH-funded study of over 12,000 mother-child pairs.
GenBio is Researching the Obesity Epidemic Affecting Over One Billion People Worldwide
May 9, 2024 / Anthocyanins obesity research / Natural obesity treatment / Gut microbiota and fat / Inflammation and metabolic health / Obesity chronic disease link
GenBio is exploring anthocyanins—natural plant compounds—as multi-target agents for obesity, demonstrating effects on inflammation, gut microbiota, lipid metabolism, and insulin resistance, with promising results in reducing fat mass and improving metabolic and cardiovascular health.
Researchers uncover why women handle body fat more efficiently
May 10, 2025 / Lipolysis gender differences / Women fat metabolism / Catecholamines and fat loss / Type 2 diabetes prevention / Metabolic health sex differences
Women exhibit more efficient fat breakdown during lipolysis, likely protecting them from metabolic diseases despite higher fat mass, with implications for developing targeted treatments to improve metabolic health and diabetes risk in men.
GLP-1 RA medications found to be safe and effective for treating obesity in adults with mental illness
May 10, 2025 / GLP-1 mental health / Obesity treatment psychiatry / Weight loss psychotropics / Semaglutide depression obesity / Safe obesity drugs mental illness
GLP-1 receptor agonists are safe and effective for weight loss and glycemic control in adults with severe mental illness, with additional benefits to mood and quality of life—showing promise for managing psychotropic-induced metabolic complications without worsening psychiatric symptoms.
Menopause at an earlier age increases risk of fatty liver disease and metabolic disorders
May 10, 2025 / Early menopause health risks / Fatty liver disease women / Menopause metabolic syndrome / MASLD and menopause / Cardiometabolic risk menopause
Early menopause, especially before age 45, significantly increases the risk of fatty liver disease and metabolic disorders within one year post-menopause, highlighting the need to include menopause timing in cardiometabolic risk assessments for women.
Mitochondrial transplantation as a strategy to address metabolic decline in aging
May 10, 2025 / Mitochondrial transplantation aging / Adipose tissue dysfunction / Exosome therapy metabolism / Insulin resistance aging / Obesity and inflammation
Mitochondrial transplantation via exosome delivery may restore adipose tissue function, counteract metabolic decline, and reduce inflammation in aging, offering a novel therapeutic strategy against obesity, insulin resistance, and age-related metabolic disorders.
Semaglutide Beneficial in Metabolic Dysfunction-Associated Steatohepatitis, Fibrosis
May 8, 2024 / Semaglutide MASH treatment / Liver fibrosis reversal / Steatohepatitis clinical trial / Weight loss semaglutide / Metabolic liver disease therapy
Semaglutide significantly improved steatohepatitis resolution and reduced liver fibrosis in patients with biopsy-confirmed MASH, also promoting substantial weight loss, according to interim results from a large phase 3 randomized trial.
Bluejay Therapeutics Reports First Preclinical Data for Liver-Targeted Fatty Acid Synthase (FASN) Inhibitor BJT-188 Being Investigated for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
May 7, 2025 / BJT-188 MASH therapy / Liver-targeted FASN inhibitor / Bluejay Therapeutics MASH / De novo lipogenesis inhibition / Fatty liver disease drug
Bluejay Therapeutics’ BJT-188, a liver-targeted FASN inhibitor, demonstrated potent inhibition of de novo lipogenesis with minimal systemic exposure in preclinical models, showing promise as a safer, effective treatment for MASH with reduced off-target toxicity risks.
Millions of women may be unaware of their risk for cardiovascular-kidney-metabolic disease
May 12, 2025 / Cardiovascular kidney metabolic health / Women heart disease risk / CKM syndrome awareness / Menopause chronic disease link / Pregnancy and metabolic health
Many women remain unaware of their interconnected risks for cardiovascular, kidney, and metabolic diseases. Early screening and attention to CKM health—especially during pregnancy and menopause—are critical to reducing disease burden and improving long-term outcomes.
New-onset mental disorders increase among patients with metabolic diseases after the COVID-19 pandemic
May 6, 2025 / COVID-19 mental health impact / Metabolic disease depression risk / Anxiety post-COVID metabolic / UK Biobank mental health / Pandemic metabolic comorbidities
Post-COVID-19, adults with metabolic diseases face significantly higher risks of new-onset depression, anxiety, and alcohol use disorders, emphasizing the need for integrated mental and metabolic health screening and interventions.
GLP-1 receptor agonists improve mood and metabolic health in adults with mental illness
May 11, 2025 / GLP-1 mental illness treatment / Psychotropic weight gain solution / Semaglutide mood benefits / Obesity and mental health / Liraglutide depression support
GLP-1 receptor agonists improve weight, glycemic control, and mood in adults with mental illness, offering a safe, effective option for managing psychotropic-induced metabolic complications while potentially enhancing emotional well-being.
Dual-Action Approach Targeting Inflammation Shows Potential as Type 1 Diabetes Treatment
May 7, 2025 / TYK2 inhibitor Type 1 diabetes / Inflammation beta cell protection / Autoimmune diabetes therapy / Psoriasis drug diabetes trial / Type 1 diabetes prevention
Blocking TYK2, an inflammation-related protein, shows promise in protecting pancreatic beta cells and reducing immune attacks in Type 1 diabetes—offering a fast-track opportunity to repurpose an existing psoriasis drug for clinical trials.
Maternal Health Risks Linked to Elevated Blood Pressure in Children
May 9, 2025 / ‘Maternal health child hypertension / Gestational diabetes offspring risk / Pregnancy blood pressure impact / Childhood cardiovascular risk / Maternal obesity child health
Maternal obesity, gestational diabetes, and hypertensive disorders during pregnancy are linked to elevated and more rapidly increasing blood pressure in children, especially girls and Black children, underscoring the importance of maternal health in shaping offspring cardiovascular risk.
The role of cardiovascular disease in the association between estimated glucose disposal rate and chronic kidney disease
May 8, 2025 / eGDR CKD risk / Insulin resistance kidney disease / Cardiovascular mediation CKD / Glucose disposal rate health / CHARLS metabolic study
Higher estimated glucose disposal rate (eGDR), a marker of insulin sensitivity, is associated with lower chronic kidney disease (CKD) risk, with cardiovascular disease mediating 27% of this link—highlighting the interplay between metabolic and vascular health in CKD development.
Ousia Pharma Secures Substantial Seed Financing Led by Omega Funds to Advance Groundbreaking Obesity Treatment
May 6, 2025 / Ousia Pharma obesity therapy / Dual-incretin NMDA conjugate / Omega Funds biotech investment / Novel obesity drug class / Neuronal targeting weight loss
Ousia Pharma secured seed funding to develop a novel obesity therapy combining dual-incretin and NMDA receptor antagonism, aiming to enhance metabolic and neuroregulatory control of appetite through targeted neuronal modulation.
Vegetarians may need to watch thyroid health, especially with low iodine intake
May 11, 2025 / Vegetarian hypothyroidism risk / Iodine deficiency thyroid / Plant-based diet thyroid health / BMI thyroid function link / Hypothyroidism and diet
Berberine shows promise in improving glycemic control and lipid metabolism via AMPK activation, but it lacks the receptor-specific action, clinical rigor, and regulatory oversight of Ozempic (semaglutide), making the “nature’s Ozempic” label scientifically inaccurate.